Browse drugs

…-1 monotherapy, whereas anti-RPLP2 was associated with irAEs in ipilimumab/nivolumab combination therapy. For ir-colitis, 38 autoantibodie…

…k M, Paz-Ares L, Creelan B, Horn L, Steins M, et al. First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. New Englan…

…, Lao CD, De Menezes JJ, et al. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N Engl J Med . 2022;386:24–34. …

…de combination ipilimumab and nivolumab, nivolumab monotherapy, pembrolizumab, and combination relatimab and nivolumab. Regarding hospitaliza…

…114 male and 50 female (unspecified 17). The ICIs involved were nivolumab (n=68), pembrolizumab (n=51), ipilimumab (n=35), atezolizumab (…

…analyzed across multiple timepoints to resolve kinetics.Results Nivolumab induced three distinct response kinetics across the CRC patient…

…nter. Patients received either nivolumab + ipilimumab (n=21) or pembrolizumab monotherapy (n=31). Radiological responses were assessed using …

…ctivation cytokines, denoting immune activation by intratumoral urelumab.Conclusions Intratumoral delivery of urelumab is feasible, safe…

…E tumour samples from NSCLC patients treated with perioperative nivolumab plus chemotherapy in the NADIM trial ( NCT03081689). Bulk RNA-s…

…e clinical trial.Methods This is an open-label phase 2 trial of ipilimumab (1 mg/kg intravenously every 6 weeks) plus nivolumab (240 mg in…

…), atezolizumab (Tecentriq), osimertinib (Tagrisso), ceritinib (Zykadia) and nintedanib (Vargatef). EMA labels for all products include…

…ase describes severe immune-mediated toxicity after one dose of ipilimumab (1 mg/kg) and nivolumab (3 mg/kg) in a stage IV patient who dev…